Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms
dc.contributor.author | Guthrie, Katherine A. | |
dc.contributor.author | LaCroix, Andrea Z. | |
dc.contributor.author | Ensrud, Kristine E. | |
dc.contributor.author | Joffe, Hadine | |
dc.contributor.author | Newton, Katherine M. | |
dc.contributor.author | Reed, Susan D. | |
dc.contributor.author | Caan, Bette | |
dc.contributor.author | Carpenter, Janet S. | |
dc.contributor.author | Cohen, Lee S. | |
dc.contributor.author | Freeman, Ellen W. | |
dc.contributor.author | Larson, Joseph C. | |
dc.contributor.author | Manson, JoAnn E. | |
dc.contributor.author | Rexrode, Kathy | |
dc.contributor.author | Skaar, Todd C. | |
dc.contributor.author | Sternfeld, Barbara | |
dc.contributor.author | Anderson, Garnet L. | |
dc.contributor.department | School of Nursing | en_US |
dc.date.accessioned | 2022-10-08T11:06:51Z | |
dc.date.available | 2022-10-08T11:06:51Z | |
dc.date.issued | 2015-08 | |
dc.description.abstract | Objective: To describe the effects of six interventions for menopausal vasomotor symptoms relative to control in a pooled analysis, facilitating translation of the results for clinicians and symptomatic women. The Menopause Strategies: Finding Lasting Answers for Symptoms and Health network tested these interventions in three randomized clinical trials. Methods: An analysis of pooled individual-level data from three randomized clinical trials is presented. Participants were 899 perimenopausal and postmenopausal women with at least 14 bothersome vasomotor symptoms per week. Interventions included 10-20 mg escitalopram per day, nonaerobic yoga, aerobic exercise, 1.8 g per day omega-3 fatty acid supplementation, 0.5 mg low-dose oral 17-beta-estradiol (E2) per day, and 75 mg low-dose venlafaxine XR per day. The main outcome measures were changes from baseline in mean daily vasomotor symptom frequency and bother during 8-12 weeks of treatment. Linear regression models estimated differences in outcomes between each intervention and corresponding control group adjusted for baseline characteristics. Models included trial-specific intercepts, effects of the baseline outcome measure, and time. Results: The 8-week reduction in vasomotor symptom frequency from baseline relative to placebo was similar for escitalopram at -1.4 per day (95% confidence interval [CI] -2.7 to -0.2), low-dose E2 at -2.4 (95% CI -3.4 to -1.3), and venlafaxine at -1.8 (95% CI -2.8 to -0.8); vasomotor symptom bother reduction was minimal and did not vary across these three pharmacologic interventions (mean -0.2 to -0.3 relative to placebo). No effects on vasomotor symptom frequency or bother were seen with aerobic exercise, yoga, or omega-3 supplements. Conclusion: These analyses suggest that escitalopram, low-dose E2, and venlafaxine provide comparable, modest reductions in vasomotor symptom frequency and bother among women with moderate hot flushes. | en_US |
dc.eprint.version | Author's manuscript | en_US |
dc.identifier.citation | Guthrie KA, LaCroix AZ, Ensrud KE, et al. Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms. Obstet Gynecol. 2015;126(2):413-422. doi:10.1097/AOG.0000000000000927 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/30270 | |
dc.language.iso | en_US | en_US |
dc.publisher | Wolters Kluwer | en_US |
dc.relation.isversionof | 10.1097/AOG.0000000000000927 | en_US |
dc.relation.journal | Obstetrics & Gynecology | en_US |
dc.rights | IUPUI Open Access Policy | en_US |
dc.source | PMC | en_US |
dc.subject | Citalopram | en_US |
dc.subject | Estradiol | en_US |
dc.subject | Omega-3 Fatty Acids | en_US |
dc.subject | Perimenopause | en_US |
dc.subject | Serotonin Uptake Inhibitors | en_US |
dc.title | Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms | en_US |
dc.type | Article | en_US |